NB100-1517

antibody from Novus Biologicals

Targeting: AKAP9 AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Antibody Data

Product number

NB100-1517

Provider

Novus Biologicals

Proper citation

Novus Cat#NB100-1517, RRID:AB_2223969

Product name

Goat Polyclonal AKAP9 Antibody

Antibody type

Polyclonal

Description

Immunogen affinity purified. This antibody is expected to recognise isoforms 2 and 3 (NP_005742.4

Reactivity

Human, Rat

Host

Goat

Isotype

IgG

Vial size

0.1 mg

Concentration

0.5 mg/ml

Storage

Store at -20C. Avoid freeze-thaw cycles.

References

Submitted references

Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes.

Christian F, Szaszák M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Götz F, Zühlke K, Moutty M, Göttert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Verli J, Gáspár R, Noack C, Bergmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E
The Journal of biological chemistry 2011 Mar 18;286(11):9079-96

---

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE
The Journal of clinical investigation 2005 Jan;115(1):94-101